John Buckingham is Principal and Portfolio Manager of Kovitz. Mr. Buckingham joined AFAM Capital in 1987 and Kovitz in 2018 as part of the Kovitz acquisition of AFAM.
He has more than 30 years of investment management experience and serves as Editor of The Prudent Speculator, which has been a trusted newsletter for over 40 years. Mr. Buckingham chairs the AFAM investment committee, leading a team that performs comprehensive investment research and financial market analysis.
In this 6,387 word interview, exclusively in the Wall Street Transcript, Mr. Buckingham stays true to his investing philosophy:
“Benjamin Graham says, when shopping for stocks, choose them the way you would buy groceries, not the way you would buy perfume.
Unfortunately, these days, we’re in an environment where investors are fascinated or fixated on stories, on companies that appear to be able to grow significantly, especially given the pandemic, and they’re paying little attention to the price they pay for those stocks.
We saw the euphoria around the Tesla (NASDAQ:TSLA) stock split, and somehow people thought that because it was cheaper in price, it was worth more, and so the stock was bid up significantly by a lot of investors, even though a stock split doesn’t alter the pie, if you will. It’s still worth the same. It should be worth the same.
I would imagine, given that many value investors have closed up shop, we’re one of the few that are left that have been disciplined, consistent and patient in implementing our strategy. ”
The Buckingham portfolio is biased towards dividend payers:
“We want to buy quality companies, we want to buy them at reasonable prices, and we want to be patient with them and milk the dividend income.
I didn’t mention dividends yet, but if you look at Fama-French data going all the way back to the 1920s, dividend-paying stocks have outperformed non-dividend-paying stocks by over 1 percentage point per annum. And by the way, they’ve done so with lower volatility.
Investors are always looking for higher returns and lower risk, if risk is defined as volatility, and market history shows that dividend payers give you the holy grail, so to speak, which is higher returns and lower risk or lower volatility.
So we do like dividend payers, and especially in the environment today, where interest rates are extraordinarily low, dividend payers make a whole lot of sense to us.”
One example of a current Buckingham pick is Nordstrom:
“For those who are willing to be maybe a little more speculative, we also recently bought Nordstrom (NYSE:JWN), which is the department store giant…in looking at Nordstrom, we think it is a name that discounts a tremendous amount of bad news.
It doesn’t discount bankruptcy, of course, but it discounts a lot of negatives that we do not think are going to materialize, so we feel we’ve got a margin of safety.
But again, it is a very volatile stock, as it has been going up and down 3% every day it seems.”
To get all of John Buckingham’s picks and the detailed analysis underlying the decisions to buy them, read the entire 6,387 word interview, exclusively in the Wall Street Transcript.
Stephen Bonnyman is Co-Head, North American Equity Research and Portfolio Manager of AGF Investments Inc.’s Canadian and global resources portfolios.
Working closely with the AGF research teams, Mr. Bonnyman focuses on identifying resource companies with solid balance sheets, advantaged cost structures, attractive valuations or unrecognized growth. Mr. Bonnyman is a member of the AGF Asset Allocation Committee, or AAC, which is comprised of senior portfolio managers who are responsible for various regions and asset classes.
In this 2,856 word interview, exclusively in the Wall Street Transcript, Mr. Bonnyman explains the philosophy underlying his portfolio management:
“This fund had some challenges because we had a couple of industries that were heavily impacted by COVID. An example of that would be the energy space, which has had a bit of a double whammy. One, a large contraction in demand resulting from the COVID-19 pandemic globally.
And secondly, the massive acceleration in the renewables theme, which has started to treat the fossil fuel industry as if it was completely dead in the water, which we don’t think is entirely the case. But that would be one very real example.
Another within our investable space would be real estate, where concerns are obviously in place as to whether the work-from-home and the COVID structures that we’ve put in place to cope are going to be longer-lasting, change the nature of how we interact and how we utilize our real estate space.”
A sector shift has been apparent in 2020:
“Right now, our largest overweights would be in utilities. And that’s a reflection of two parts. One, the interest rate structure that reflects utilities. And secondly, the bulk of that exposure exists within the renewable schemes, so names like NextEra (NYSE:NEE), Boralex (OTCMKTS:BRLXF), NPI (TSE:NPI), where we’re looking at specific themes.
Where are we underweight at the moment? We are underweight real estate. Obviously, the challenges facing the market right now have not played out. And I think we’ve got to look at how many of these survived through this structure.”
Mr. Bonnyman sees an immediate opportunity in silver investing:
“I might add, SilverCrest, we own in a large part because of its valuation. This, in our eyes, was one of the most exciting exploration plays available within our sort of investable framework.
And we’ve been invested in the company for quite a long time since it emerged as a junior exploration company. So while we like silver, our ownership of SilverCrest is based more upon the exploration and development capability of the company than necessarily on its underlying commodities.
To answer your question directly, yes, we do like silver. The silver market is a combination of gold and an industrial metal. It’s sometimes referred to as gold on steroids.
As we get through the election, as we start to emerge from the pandemic, industrial demand for silver will accelerate and increase. And we think it has, in fact, a higher return potential than gold as a raw metal from this point forward.”
To get the complete interview with Mr. Bonnyman, read the entire 2,856 word interview, exclusively in the Wall Street Transcript.
David Corris, CFA, is the Head of Disciplined Equities and Portfolio Manager, Disciplined Equities at BMO Global Asset Management.
Mr. Corris heads the BMO Disciplined Equity Team and is responsible for equity portfolio management and research. He joined the company in 2008. Mr. Corris began his investment management career in 1999 and was a quantitative equity portfolio manager/researcher at Northern Trust Global Investments and a quantitative equity research analyst at Citigroup Asset Management.
He holds an MBA from Harvard Business School and a B.S. in mathematics and quantitative economics from the University of Wisconsin.
In this 2,426 word interview, exclusively with the Wall Street Transcript, Mr. Corris sees some investment opportunities at hand.
“…We think that for investors with a moderate time frame, small-cap value is best positioned in the current market. Large-cap growth has been leading the market for the last couple of years, and small-cap value has underperformed significantly.
Our research shows that typically small-cap and value strategies outperform coming out of recessions. And what’s really interesting this year is that although the market has rebounded fully since the beginning of the year, small-cap value has still continued to lag large growth, not only on the way down but also on the way back up.”
The political process provides portfolio picks:
“I can give you a few names that tie into both the Democratic and Republican exposures. Two areas where we are overweight right now are industrials and materials.
I mentioned infrastructure would probably benefit on the Democratic side.
One name we like there is U.S. Concrete (NASDAQ:USCR), which is a leading producer of concrete, selling into commercial, industrial and residential channels. They should be a beneficiary of infrastructure stimulus, and they are a large national player.
Another example is MYR Group (NASDAQ:MYRG). They provide specialized electrical infrastructure to U.S. electric utilities. And so as utility spending increases, as they upgrade or fortify the grid, we would expect MYR Group to benefit from that.
I also mentioned renewable energy. An example in that space would be Renewable Energy Group (NASDAQ:REGI).
Renewable Energy Group is the leader in producing renewable diesel. They’re very profitable, a company with a strong balance sheet, and they’re looking to expand into additional renewable markets.
We would note that you typically don’t find a lot of small-cap value clean energy names, but we think this is a name that not only is attractive on its own merits but also thematically as the market continues to embrace ESG and responsible investing.
On the Republican side, I’d mention banks because they tend to be a large weight in the small-cap value benchmark; however, a lot of our peers typically underweight them because they tend to be less liquid.
One of the things that we’ve always built into our strategy is tight liquidity control, which allows us to build baskets of stocks to make sure that we get exposures to large parts of the benchmark that may have liquidity challenges, and banks would be a good example of that.
We own a number of banks, ranging from Cathay General (NASDAQ:CATY) to Wintrust (NASDAQ:WTFC), First Merchants Corporation (NASDAQ:FRME) and Zions (NASDAQ:ZION), all of which help ensure that we have adequate bank exposure in the event that the banks recover from here.”
Get more of Mr. Corris’ portfolio reasoning by reading the entire 2,426 word interview, exclusively with the Wall Street Transcript.
Christopher Tsai is President and Chief Investment Officer of Tsai Capital Corporation, a value-oriented investment management firm focused on the long-term growth and preservation of capital. He founded the company in 1997 and is Chairperson of the firm’s advisory committee.
Prior to forming Tsai Capital, he was an equity analyst at Bear, Stearns & Co. Inc., John A. Levin & Co., Inc. and Gabelli Asset Management. Mr. Tsai has been profiled in numerous financial publications including Barron’s, Bloomberg, Financial Planning, Investment Advisor magazine, The Wall Street Transcript and Wealth Management magazine, and has been interviewed by Bloomberg Radio, China Money Network, Fox Business Network, MOI Global, Nasdaq and Yahoo Finance Live.
In this 3,211 word interview, exclusively in the Wall Street Transcript, Mr. Tsai explores the world of long term investing:
“Our focus has been really on two main objectives, compounding capital over the long term and the preservation of our clients’ capital.
What I think separates Tsai Capital from the vast majority of other managers is our key disciplines: One of them being a focus on concentration rather than broad diversification, and the other being a truly long-term mindset.
For us, the ideal business is a business that we can own indefinitely, and we go into an investment with that mindset.”
This investment philosophy leads to a very selective stock picking process:
“What’s a compounder? We define a compounder as a high-quality company that has a durable competitive advantage and can reinvest capital at high rates of return over a long duration.
These kinds of businesses are often very difficult to buy at reasonable valuations because everybody else knows that they are superior businesses. We do our research upfront, often several years in advance of actually making an acquisition. We’re extremely patient. If we can’t find anything to buy, so be it; we’ll hold cash.”
It sometimes leads to some counterintuitive results:
February and March were particularly rough months for the vast majority of companies, including one business that we have increasingly admired over the past few years.
In February and in March, Tesla (NASDAQ:TSLA) sold off substantially after having run up in the previous months. That was our opportunity. We had done a lot of work on the business prior to February, so we were in a position to act decisively when most of Wall Street was going the other way and selling the stock.
I mentioned that we like businesses that we can own indefinitely, businesses that can compound capital and reinvest profits at high rates of return over a long duration. Tesla fits very much into that category. And when we bought it, I think it was very cheap.
So why Tesla? My late father, who was an investor in his own right, was great at identifying long-term trends. He learned from my grandmother, Ruth, who was the only woman to trade shares on the Shanghai Stock Exchange during World War II, the importance of positioning yourself with the wind at your back.
And the wind here is the long-term trend toward electrification of both passenger and commercial vehicles.”
Get the rest of Mr. Tsai’s Tesla valuation and many more interesting stock picks by reading the entire 3,211 word interview, exclusively in the Wall Street Transcript.
Brian Yacktman is Chief Investment Officer, Portfolio Manager of YCG Enhanced Fund and Founding Partner of YCG, LLC. Mr. Yacktman has served as Chief Investment Officer and Portfolio Manager since the inception of the fund.
Elliott Savage is Portfolio Manager of YCG Enhanced Fund and Partner of YCG, LLC. Mr. Savage has served as Portfolio Manager since the inception of the fund. Prior to joining YCG in 2012, Mr. Savage was a senior analyst at Highside Capital Management, a multibillion-dollar long/short equity hedge fund located in Dallas, Texas.
In this 4,470 word interview, exclusively in the Wall Street Transcript, Mr. Yacktman and Mr. Savage detail their investing philosophy and explore many of their top stock picks.
“What we are really after are businesses that, in a world of competition and innovation, continually earn a high return on their tangible assets or owner’s equity over long periods of time.
Competition and innovation step in and drive down pricing. We are looking for businesses where, regardless of the competition that may come their way, there is something unique or special about them, and this allows them to maintain pricing power in the face of competition and innovation. We find that most often among businesses that exhibit some form of network economics.”
The network effect is a key component of the investing thesis:
“A lot of industries are shrinking and becoming smaller portions of GDP over time. That is going to create a headwind to your pricing power.
In contrast, take the advertising industry. If your competitor’s advertising a lot, you need to advertise a lot. Therefore, what you see is, advertising has maintained its share of GDP at about, let’s just say, 1% of GDP over time.
Then, if you can find businesses that maintain pricing power, like Google (NASDAQ:GOOG) or Facebook (NASDAQ:FB), due to their network effects, that allows them to essentially become a toll taker on global advertising.
Another example would be insurance brokerages where the insurance industry has maintained its share of GDP over time, more or less. It almost looks like a sine or cosine wave, as insurance premiums harden and soften over time, but it has maintained its share more or less over time.
And then, these insurance brokerages, due to their strong networks and sticky relationships, maintain their pricing power on global insurance activity. It is almost like these businesses have built-in growth that’s indexed to GDP plus.”
One drag on the portfolio has been their banking bets, although this may mean an opportunity for new investors:
“Our concern has been, should you have interest rate or inflation surprises to the upside, then those valuation multiples are going to compress pretty rapidly, and we wanted to have something that could act as a hedge in the portfolio against that, and what’s beautiful about the banking industry — so we’re speaking of the three largest U.S. depositors: JPMorgan Chase (NYSE:JPM), Bank of America (NYSE:BAC), Wells Fargo (NYSE:WFC), with Wells Fargo being sort of the contrarian piece, as well as Charles Schwab (NYSE:SCHW), the largest discount brokerage — is these businesses are leveraged to rising interest rates.
In contrast to almost all of the other businesses, their earning power would actually increase because we are so close to the zero-bound that it is squeezing their profits. As their profitability increases, likely what would happen is, the multiples that investors are willing to pay for those businesses would also expand, again, in contrast to almost all of the other businesses. So you could get a double benefit to help hedge against the compression you are experiencing in other businesses.
But unfortunately, as anyone can tell, due to coronavirus, interest rates have dropped to zero and may actually go into negative territory, which is an extra negative to them, as well as the fear of bad loans and how this will all shake out.
It has been a real drag on the portfolio, and had we exited that portion of the portfolio, we would have looked like geniuses, but we recognize that part of having a hedge in your portfolio means that it won’t always work and sometimes can actually be a detractor, and that’s what’s happened in this instance.”
Get the full detail on all the portfolio hits and misses from this 4,470 word interview with Mr. Yacktman and Mr. Savage exclusively in the Wall Street Transcript.
Brian Yacktman, Chief Investment Officer, Portfolio Manager & Founding Partner
Elliott Savage, Portfolio Manager & Partner
email: info@ycgfunds.com
Stephen J. Fauer, CFA, is Pinnacle Capital Management Chief Investment Officer and Principal Portfolio Manager. He has served in these roles since Pinnacle Capital Management’s founding in 2006, overseeing all separately managed and mutual fund portfolios totaling in excess of $100 million in assets.
In this 3,031 word interview, exclusively in the Wall Street Transcript, Mr. Fauer takes investors through the top picks in his publicly traded portfolio and reveals some interesting details that demonstrate their upside:
“Right now, in terms of sectors, we have a bit of what I’ll call “surviving retail” — those companies that will do well going forward that have survived this COVID downturn. We have Dick’s Sporting Goods (NYSE:DKS). We have Walmart (NYSE:WMT). We have CVS (NYSE:CVS).
We also like the telcos. We think 5G is going to be a big thing, not necessarily in terms of handsets in the next year or two, but long term.
We’re very much long-term investors for our clients. We’re not trying to catch the latest hot trend. We’re not trying to figure out who’s going to pick up 5 percentage points of market share in the chip business in the next three months. We don’t try to do that, as we think that’s too hard. You can’t beat the market on knowledge, but we think we can over time beat it with perspective.”
Stephen Fauer also sees other overlooked large cap names that will benefit from a 2nd wave of COVID austerity:
“We also have a couple of the food companies because people still have to eat. We own Mondelez (NASDAQ:MDLZ); they’ve got snacks and candies and a few other things there. We’ve got Kellogg (NYSE:K).
I think people eating at home, that’s going to be a long-term trend. Eating at home, you’re more likely to eat cereal. We’ve owned Unilever (NYSE:UL) for quite some time.
We used to own United Technologies. With its break up, we own all three pieces — Raytheon (NYSE:RTX), Otis (NYSE:OTIS) and Carrier (NYSE:CARR) — but we actually think Carrier over the long term is the best of the three sectors. We really like that stock.
I think one of the things that’s coming out of COVID is that, first of all, air filtering systems are going to be important.
I don’t think it’ll stop once there’s some kind of treatment or vaccine. Also, there’s going to be a movement — and it’s already been well-documented — out of the major cities, more into the suburbs. That means different kinds of building. I think that will benefit them over the long run. So that’s another one of our holdings that we very much like.”
Get more of these stock picks and additional details by reading the entire Stephen Fauer 3,031 word interview, exclusively in the Wall Street Transcript.
Jason Kish became a Portfolio Manager at Prospector Partners, LLC in 2013 and has been with the investment manager since December 1997. He is also a portfolio manager of Prospector Partners Asset Management, LLC. Mr. Kish has been a portfolio manager or securities analyst for more than 20 years.
In this 3,846 word interview, exclusively in the Wall Street Transcript, Mr. Kish details the investment philosophy that guides his firm’s portfolio management.
“Initially, the product offered was a financial-services-focused long/short fund. And then, down the road, in 2007, we added the two mutual funds, the Prospector Opportunity Fund (MUTF:POPFX) and the Prospector Capital Appreciation Fund (MUTF:PCAFX).
Not ideal timing for a value shop ahead of a long period of growth dominating and just ahead of the great financial crisis, but we’ve done OK with the funds.
And then, we became subadviser for a 1940 Act long/short fund, LSOFX, about five years ago.
Today, we have 14 employees. We manage about $700 million in assets. There are four PMs, myself included, who also function as analysts.
We get our hands very dirty in the research process. And we have three industry-specialist analysts… I would say how we feel we differ from many managers is we focus on the downside first for every idea.
We first ask, “How much could we lose?” where we feel a lot of people look at an idea and say, “How much can I make?” We’ll pass on an idea if we think there’s 25% or more downside.”
This is more specific in valuation:
“…Basically, private market value recognizes the difference between GAAP and intrinsic value, so we like using that. And the second would be free cash flow yield.
We like companies that produce solid, consistent cash flows, which typically makes them less reliant on capital markets for financing, and we think those types of companies exhibit more owner-oriented behavior.”
An example is illustrative:
“I’m happy to talk about one of the convert ideas to give you a little flavor for how we invest in converts. A good example of a convert we own is Palo Alto Networks (NYSE:PANW), which is a global cybersecurity company.
They’re the leader in network firewalls. The company a couple of years ago brought in a new CEO, Nikesh Arora from Google, and he’s been transitioning the company to more provide the full suite of security products.
As companies move to the cloud, it’s become necessary to transition their strategy a bit. They seem to be executing well, and they actually should be aided by the whole work-from-home trend as cybersecurity becomes even more of a priority.
The convert matures July 2023, and right now, it’s trading around $111 or $112. But we like the fact that the company has a rock-solid balance sheet, about $300 million of net cash on the balance sheet, and they produce over $1 billion of free cash flow per year.
It’s trading over 5% forward free cash flow yield. So by buying the convert here, we believe it offers pretty limited downside to par and decent participation in the upside. The convert feature is in the money at $266 per share versus the current price of the stock in the high $230s. Given that you have three years to maturity, the delta is right around .55.”
To get more details on this and many other examples, read the entire 3,846 word interview, exclusively in the Wall Street Transcript.
David Nierengarten, Ph.D., is Managing Director and Head of Healthcare Equity Research at Wedbush Securities.
He mainly covers development-stage therapeutic companies. He began his career on the financial side of biotechnology at a venture capital firm that focused on early-stage therapeutic and medical device companies.
Additionally, prior to joining Wedbush, he worked in a clinical-stage, venture-backed biotechnology company, in business development and clinical trial operations. He received his bachelor’s degree in biochemistry from the University of Wisconsin-Madison and his Ph.D. in molecular and cell biology from the University of California-Berkeley.
In this 3,444 word interview, exclusively in the Wall Street Transcript, Dr. Nierengarten details his current biotech sector investment forecast.
“…There’s also been a resurgence in what I would call the next generation of cell therapies for cancer.
So moving beyond the initial approved autologous T cell, engineered T-cell therapies of Yescarta and Kymriah, and moving into allogeneic or more broadly applicable engineered cell technologies that could potentially treat a wider variety of cancers.
For example, Fate Therapeutics (NASDAQ:FATE) is working with pluripotent-derived natural killer cells — NK cells — in this area.
The other trend or noticeable events over the last few months are perhaps the little bit more scrutiny the FDA has applied to gene therapies, particularly ones where there are existing alternative therapies, such as the CRL — complete response letter — that was given to BioMarin (NASDAQ:BMRN) for Roctavian, their gene therapy for hemophilia.
That was a bit of a surprise to the industry generally. And I think probably speaks to a little bit more scrutiny specifically for diseases where there are existing therapies, and the FDA might want to have a bigger body of evidence for durable, lasting, meaningful clinical benefit for those kinds of therapies.”
Despite the greater FDA scrutiny for genetic therapies, Dr. Nierengarten sees potential in many biotech stocks:
“There are several throughout the space. First, on the genetic-medicine side, there are a couple of earlier stage, a couple of later stage, depending on investors’ appetites.
But one of the later-stage companies — it actually is going to be reporting data on September 9 — is AGTC (NASDAQ:AGTC), and they have a gene therapy for a rare retinal disease, X-linked retinitis pigmentosa, that should be progressing into a Phase III study by the end of the year.
It’s a pretty small market cap given the opportunity of several thousand patients with this rare form of disease that causes blindness in a relatively advanced stage of development.
Other genetic medicines, again, maybe more broadly applied, are some of the earlier-stage companies like Beam Therapeutics (NASDAQ:BEAM) that has a new gene-editing technology that they’re putting into the preclinical experiments right now.
And one that has a really broad potential: Generation Bio (NASDAQ:GBIO). That’s a recent IPO. And Generation Bio is really looking at eliminating a significant bottleneck in gene therapy, and that’s the virus sector.
So to deliver gene therapy, you need to genetically engineer a virus to deliver the genetic material to the cells. Generation Bio is looking to avoid that completely by packaging up the DNA and lipid nanoparticles, these little particles that they inject, and it gets into the cells, puts the genetic material in the cells to make a protein of interest that’s either defective in the patient or has other therapeutic value.
On the oncology side, a couple of names in the small-molecule-targeted therapies. One is Epizyme (NASDAQ:EPZM).
They have an approved drug actually. I think it’s a very good value for their approved drug, Tazverik. That’s approved in both a rare epithelioid sarcoma indication but more broadly or a larger indication of follicular lymphoma. They’re just launching that drug right now. And I think it has potential to outperform expectations.
And also, on the targeted side of things, Blueprint Medicines (NASDAQ:BPMC) just got their drug approved for RET fusion-positive lung cancers.”
Get the complete detail on these and other biotech stocks, exclusively in this 3,444 word interview with David Nierengarten, Ph.D., Managing Director and Head of Healthcare Equity Research at Wedbush Securities.
Dr. James Garner is Chief Executive Officer and Executive Director of Kazia Therapeutics Limited. In this 3,500 word interview, found exclusively in the Wall Street Transcript, Dr. Garner explains the upside for investors in his company:
“Our lead drug is paxalisib, formerly known as GDC-0084. This drug is under development for multiple forms of brain cancer but with a primary focus on a disease called glioblastoma, which is the most common and the most aggressive form of brain cancer.
This was the disease that, for example, took the life of U.S. Senator John McCain, the Republican senator for Arizona, a year or two back.
Glioblastoma is a really difficult disease to treat. It affects about 12,500 Americans each year, and it really has one of the worst prognoses of any cancer out there. Life expectancy from diagnosis is typically between about 12 months and 15 months, and that really hasn’t improved this century.”
The therapy is currently being tested in the US:
“The unique feature about paxalisib is that it’s the only drug of its kind that is able to cross the blood-brain barrier. It’s the only drug that can get into the brain.
Ordinarily, the blood-brain barrier prevents most drugs and toxins from getting into the brain as a protective mechanism, but it does make it very hard treating brain disease, whether that be Parkinson’s disease, depression, brain cancer and so on. Paxalisib is able to cross the blood-brain barrier — it gets into the brain — and that gives it a unique advantage in terms of the treatment of this disease.
So unsurprisingly, we are looking at the drug in other forms of brain cancer as well. In addition to glioblastoma, we have a study going on in a rare childhood brain cancer called DIPG. Thankfully, this is not a common disease. It affects only about 400 or 500 kids a year in the United States, but it is a devastating disease for patients and for their families.
It typically affects kids between about 4 and 12 years of age. Life expectancy from diagnosis is about nine or 10 months. And there are no FDA-approved treatments. Really, all we have for kids with DIPG is palliative radiotherapy.
We’re doing a study with St. Jude Children’s Research Hospital in Memphis, Tennessee, to see if our drug, paxalisib, is able to offer some benefit here in DIPG. We’re expecting to see data there, hopefully, by the end of this year. I think if we can make a difference there, it’d be very exciting news.”
Get the complete detail by reading the entire 3,500 word interview, exclusively in the Wall Street Transcript.
Michael Quaid was appointed CEO of Boomer Holdings, Inc. at its formation in August 2019. Earlier, he was the majority owner and Managing Director of Typhoon FX trading platforms. Previously, Mr. Quaid was Managing Partner at KCCO II Trading and was head of European derivatives for S.G. Warburg & Co. in London.
In this 2,859 word interview, exclusively in the Wall Street Transcript, Mr. Quaid details his company’s prospects for investors.
“The company has two divisions: the Healthy Living Division and the PPE — personal protective equipment — Division. The Healthy Living Division features our doctor-formulated Boomer Botanics line. This line is actually an alternative to CBD.
It features all-natural ingredients, which are FDA-compliant. The products promote a strong immune system and can help with inflammatory issues, pain and anxiety.
We have co-branded these products with Tommy Bahama. Brandt Jobe, who is a professional golfer on the PGA Champions Tour, is our spokesman for the sports world.
The PPE Division was developed in the spring of 2020 in concert with our Medical Advisory Board. We have a multitude of offerings, but our flagship product is our Boomer Naturals’ reusable face mask.
Our face masks are WHO- and CDC-compliant. They have three layers of cotton-poly infused nanosilver technology. They’ve tested out at 99.99% anti-microbial. They come in six sizes — four adult sizes, two children sizes — and would be considered our flagship product.”
The Tommy Bahama botanical treatment has seen early success:
“And I will tell you that most people that try those Botanics products fall in love with them. We were at the PGA Merchandise Show in January, and we handed out a lot of our pain roll-ons, thousands of them.
And over the next two or three days after we handed them out, people just kept coming back saying, “You may have just changed my life. This gave me instant relief, and I’ve never had anything else like it.” We’ve heard that from so many people. And to get the feedback from our distribution networks in the chiropractic world, it’s something that once people try it, they like it, and they’ll keep using it.”
The company is also selling and distributing PPE:
“…the New York City Department of Veteran Services, we were able to get them 40,000 masks, also a partnership with Partnership With Native Americans, or PWNA, Boys and Girls Clubs in several cities and several schools that were truly in need of these face masks.
A lot of the school systems set up guidelines and didn’t come through with the funding. And so where there was a need and we could help out, we did so. We’re thrilled to do that. We continue to do it.”
Get the compete detail on this newly public company by reading the entire 2,859 word interview, only in the Wall Street Transcript.
